7509-61-7

Usage

Uses

Used in Organic Synthesis:
(2E)-N-(2-Ethylphenyl)-2-(hydroxyimino)acetamide is utilized as a reagent in the preparation of a wide range of organic compounds. Its ability to act as a versatile precursor allows for the synthesis of different functional groups, making it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2E)-N-(2-Ethylphenyl)-2-(hydroxyimino)acetamide is employed as a building block for the development of heterocyclic compounds and other biologically active molecules. Its role in the synthesis of such compounds contributes to the advancement of new drug candidates and therapeutic agents.
Used in Chemical Research:
(2E)-N-(2-Ethylphenyl)-2-(hydroxyimino)acetamide also serves as an important tool in chemical research, where it is used to explore novel reactions and mechanisms. Its unique properties and reactivity make it a useful probe for understanding the behavior of various organic systems and advancing the field of organic chemistry.

InChI:InChI=1/C10H12N2O2/c1-2-8-5-3-4-6-9(8)12-10(13)7-11-14/h3-7,14H,2H2,1H3,(H,12,13)

Upstream product

• 302-17-0 chloral hydrate 
• 578-54-1 ortho-ethylaniline 

Downstream Products

• 79183-65-6 7-ethylisatin 
• 5437-40-1 2-amino-3-ethylbenzoic acid 
• 1067186-32-6 8-ethyl-3-hydroxy-2-(1-phenylcyclopropyl)quinoline-4-carboxylic acid 

Relevant academic research and scientific papers

Palladium(II)/N-Heterocyclic Carbene Catalyzed One-Pot Sequential α-Arylation/Alkylation: Access to 3,3-Disubstituted Oxindoles

Rationally designed fluorene-based mono- and bimetallic Pd-PEPPSI complexes were synthesized and demonstrated to be effective for the one-pot sequential α-arylation/alkylation of oxindoles. This streamlined approach offers efficient access to functionalized 3,3-disubstituted oxindoles in excellent yields (up to 89%) under mild reaction conditions.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

Methods and Compositions for Selectin Inhibition

The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

Deamination of 1-alkyl-9-aminomethyltriptycenes. Participation of a neighboring 1-alkyl substituent

Deamination reactions of 1-alkyl-9-aminomethyltriptycenes (alkyl = Me, Et, i-Pr, and t-Bu) and 9-(1-aminoethyl)-1-methyltriptycene were performed in CHCl3 and in AcOH, and product distributions were studied. The results suggest that the loss of

Condensed bridgehead nitrogen heterocyclic systems: Synthesis and antimicrobial activity of thiazolo[3′, 2′: 2, 3]-as-triazino[5, 6-b]indoles and isomeric thiazolo[2′, 3′: 3, 4]-as-triazino[5, 6-b]indoles

2, 3-Dihydro-6-ethyl-5H-as-triazino[5, 6-b]indole-3-thione 4 on condensation with α-haloketone gives 3-aroylmethylthio-6-ethyl-5H-as-triazino[5, 6-b]indolehydrobromide 5 which on PPA catalyzed cyclization furnishes 3-aryl-9-ethylthiazolo[3′, 2′: 2, 3]-as-